{"DataElement":{"publicId":"5077278","version":"1","preferredName":"Recombinant Granulocyte Colony-Stimulating Factor Administered Type","preferredDefinition":"A description of the recombinant granulocyte colony-stimulating factor that was administered.","longName":"2873951v1.0:2775103v2.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2873951","version":"1","preferredName":"Recombinant Granulocyte Colony-Stimulating Factor Administered","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)_The act of having given something (e.g., a medication or test).","longName":"G_CSF_ADM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2582947","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor","preferredDefinition":"G-CSF. A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell).  It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called filgrastim.","longName":"C1287","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte Colony-Stimulating Factor","conceptCode":"C1287","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"258399ED-7A5D-2319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-26","modifiedBy":"ONEDATA","dateModified":"2006-12-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"696CFB00-2220-EAFA-E040-BB89AD436EFA","latestVersionIndicator":"Yes","beginDate":"2009-05-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2775103","version":"2","preferredName":"Recombinant Granulocyte Colony-Stimulating Factor Type","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)_Type; a subdivision of a particular kind of thing.","longName":"2775103v2.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Filgrastim","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"2576855","version":"1","preferredName":"Filgrastim","longName":"2576855","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F944-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3B4E-564F-E050-BB89AD436E50","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"},{"value":"Other drug","valueDescription":"Other","ValueMeaning":{"publicId":"5037694","version":"1","preferredName":"Other","longName":"5037694","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22B5B587-3B58-564F-E050-BB89AD436E50","latestVersionIndicator":"Yes","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3B70-564F-E050-BB89AD436E50","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"},{"value":"Lenograstim","valueDescription":"Lenograstim","ValueMeaning":{"publicId":"2582535","version":"1","preferredName":"Lenograstim","longName":"2582535","preferredDefinition":"A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenograstim","conceptCode":"C49234","definition":"A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0F74-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-19","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-12-19","modifiedBy":"ONEDATA","dateModified":"2006-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3B17-564F-E050-BB89AD436E50","beginDate":"2008-08-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"},{"value":"Pegfilgrastim","valueDescription":"Pegfilgrastim","ValueMeaning":{"publicId":"2775105","version":"1","preferredName":"Pegfilgrastim","longName":"2775105","preferredDefinition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegfilgrastim","conceptCode":"C1854","definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D3AA38-DF52-52EA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3B44-564F-E050-BB89AD436E50","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"},{"value":"TBO filgrastim","valueDescription":"Tbo-filgrastim","ValueMeaning":{"publicId":"5916940","version":"1","preferredName":"Tbo-filgrastim","longName":"5916940","preferredDefinition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Tbo-filgrastim specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tbo-filgrastim","conceptCode":"C137803","definition":"A recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Upon administration, tbo-filgrastim specifically binds to and activates G-CSF receptors, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This stimulates the proliferation of neutrophils and may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN). The pharmacokinetic and pharmacodynamic profile of tbo-filgrastim is bioequivalent to filgrastim.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55C47452-286D-63D9-E053-F662850ACF4B","latestVersionIndicator":"Yes","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55C47452-2886-63D9-E053-F662850ACF4B","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"ONEDATA","dateModified":"2017-08-02","deletedIndicator":"No"},{"value":"Filgrastim-sndz","valueDescription":"Filgrastim-sndz","ValueMeaning":{"publicId":"5916941","version":"1","preferredName":"Filgrastim-sndz","longName":"5916941","preferredDefinition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Filgrastim-sndz specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim-sndz","conceptCode":"C137804","definition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Filgrastim-sndz specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55C47452-2892-63D9-E053-F662850ACF4B","latestVersionIndicator":"Yes","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55C47452-28AA-63D9-E053-F662850ACF4B","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"ONEDATA","dateModified":"2017-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2557250","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor Type","preferredDefinition":"G-CSF. A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell).  It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called filgrastim.:Type; a subdivision of a particular kind of thing.","longName":"C1287:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte Colony-Stimulating Factor","conceptCode":"C1287","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24FB5B03-99CC-687B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-19","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-12-19","modifiedBy":"ONEDATA","dateModified":"2006-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"22B5B587-3AED-564F-E050-BB89AD436E50","latestVersionIndicator":"Yes","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"KUMMEROA","dateModified":"2017-08-02","changeDescription":". Added 2 PVs for 2565. AK 8//2/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_GFCT_g_csf_type","type":"NMDP_FN","context":"NHLBI"},{"name":"SNFM_GCSFM_gcsf_mob_agt_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the recombinant gran","type":"Preferred Question Text","description":"What was the recombinant granulocyte colony-stimulating factor that was administered?","url":null,"context":"NHLBI"},{"name":"Specify drug given","type":"Alternate Question Text","description":"Specify drug given","url":null,"context":"NHLBI"},{"name":"Specify drug given","type":"Application Standard Question Text","description":"Specify drug given","url":null,"context":"NHLBI"},{"name":"Specify type of G-CSF","type":"Alternate Question Text","description":"Specify type of G-CSF","url":null,"context":"NHLBI"},{"name":"Specify G-CSF drug given","type":"Alternate Question Text","description":"Specify G-CSF drug given","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2665A738-82F5-6D43-E050-BB89AD43625F","latestVersionIndicator":"Yes","beginDate":"2015-12-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-08","modifiedBy":"MALUMK","dateModified":"2021-03-23","changeDescription":".Added AQT for 2565r1  2017-08-04 SLS. AQT added for 2100r7. 03/23/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}